Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol.
Kotwal SS, Perkovic V, Jardine MJ, Kim D, Shah NA, Lin E, Coggan S, Billot L, Vart P, Wheeler DC, de Boer IH, Zhang H, Hou FF, Sugawara Y, Marion J, Lewis RJ, Berry LR, McGlothlin A, Jha V, De Nicola L, Gorriz JL, Heerspink HJL; GKPTN and CAPTIVATE Investigators. Kotwal SS, et al. Among authors: de nicola l. JAMA Netw Open. 2024 Dec 2;7(12):e2449998. doi: 10.1001/jamanetworkopen.2024.49998. JAMA Netw Open. 2024. PMID: 39661388 Free PMC article.
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.
Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators. Jardine MJ, et al. Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. Online ahead of print. Am J Nephrol. 2017. PMID: 29253846 Free PMC article.
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
Yi TW, Smyth B, Di Tanna GL, Arnott C, Cardoza K, Kang A, Pollock C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Heerspink HJL, Neal B, Wheeler DC, Cannon CP, Zhang H, Zinman B, Perkovic V, Levin A, Mahaffey KW, Jardine M; CREDENCE Trial Investigators. Yi TW, et al. Am J Kidney Dis. 2023 Jul;82(1):84-96.e1. doi: 10.1053/j.ajkd.2022.12.015. Epub 2023 Mar 7. Am J Kidney Dis. 2023. PMID: 36889425 Clinical Trial.
Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis.
McEwan P, Hafner M, Jha V, Correa-Rotter R, Chernin G, De Nicola L, Villanueva R, Wheeler DC, Barone S, Nolan S, Garcia Sanchez JJ. McEwan P, et al. Among authors: de nicola l. J Med Econ. 2023 Jan-Dec;26(1):1407-1416. doi: 10.1080/13696998.2023.2264715. Epub 2023 Oct 31. J Med Econ. 2023. PMID: 37807895 Free article. Review.
Glomerular and tubular effects of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease: A post-hoc analysis of the ROTATE-3 study.
Lieverse TTGF, Puchades MJ, Mulder UDJ, Provenzano M, Krenning G, Jongs N, Wink SE, Slart RHJA, Andreucci M, D'Marco L, De Nicola L, Gorriz JL, Heerspink HJL. Lieverse TTGF, et al. Among authors: de nicola l. Diabetes Obes Metab. 2024 Feb;26(2):576-582. doi: 10.1111/dom.15346. Epub 2023 Nov 5. Diabetes Obes Metab. 2024. PMID: 37926904 Clinical Trial.
Suboptimal monitoring and management in patients with unrecorded stage 3 chronic kidney disease in real-world settings: Insights from REVEAL-CKD.
Tangri N, Alvarez CS, Arnold M, Barone S, Cebrián A, Chen H, De Nicola L, Järbrink K, Kanumilli N, Lim KS, Moriyama T, Pecoits Filho R, Ribeiro de Castro MC, Santamaria R, Schneider MP, Virgitti JB, Kushner P. Tangri N, et al. Among authors: de nicola l. Eur J Clin Invest. 2024 Nov;54(11):e14282. doi: 10.1111/eci.14282. Epub 2024 Jul 18. Eur J Clin Invest. 2024. PMID: 39023418
Hyperkalemia in CKD: an overview of available therapeutic strategies.
Costa D, Patella G, Provenzano M, Ielapi N, Faga T, Zicarelli M, Arturi F, Coppolino G, Bolignano D, De Sarro G, Bracale UM, De Nicola L, Chiodini P, Serra R, Andreucci M. Costa D, et al. Among authors: de nicola l, de sarro g. Front Med (Lausanne). 2023 Jul 31;10:1178140. doi: 10.3389/fmed.2023.1178140. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37583425 Free PMC article. Review.
Prognosis of CKD patients receiving outpatient nephrology care in Italy.
De Nicola L, Chiodini P, Zoccali C, Borrelli S, Cianciaruso B, Di Iorio B, Santoro D, Giancaspro V, Abaterusso C, Gallo C, Conte G, Minutolo R; SIN-TABLE CKD Study Group. De Nicola L, et al. Clin J Am Soc Nephrol. 2011 Oct;6(10):2421-8. doi: 10.2215/CJN.01180211. Epub 2011 Aug 4. Clin J Am Soc Nephrol. 2011. PMID: 21817127 Free PMC article.
Sodium-glucose cotransporter-2 inhibition in a CKD patient with severe heart failure treated by high-dose diuretics and peritoneal ultrafiltration: lesson for the clinical nephrologist.
Borrelli S, Garofalo C, Liberti ME, Ruotolo C, Capozzi F, Yavorskiy P, De Nicola L. Borrelli S, et al. Among authors: de nicola l. J Nephrol. 2024 Jan;37(1):199-201. doi: 10.1007/s40620-023-01766-x. Epub 2023 Sep 14. J Nephrol. 2024. PMID: 37707693 No abstract available.
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
Barratt J, Dellanna F, Portoles J, Choukroun G, De Nicola L, Young J, Dimković N, Reusch M. Barratt J, et al. Among authors: de nicola l. Adv Ther. 2023 Apr;40(4):1546-1559. doi: 10.1007/s12325-023-02433-0. Epub 2023 Feb 7. Adv Ther. 2023. PMID: 36749544 Free PMC article. Clinical Trial.
326 results